NKTX Nkarta

Nkarta to Participate at Upcoming Investor Conferences

Nkarta to Participate at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at these upcoming investor conferences:

Cowen 5th Annual IO Next Summit

November 15, 2021

11:15 a.m. ET - fireside chat presentation

Stifel 2021 Virtual Healthcare Conference

November 17, 2021

2:00 p.m. ET – fireside chat presentation

Evercore ISI 4th Annual HealthCONx Conference

December 1, 2021

4:20 p.m. ET – fireside chat presentation

A simultaneous webcast of the presentations will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately four weeks.

About Nkarta

Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at .

Nkarta Media/Investor Contact:

Greg Mann

Nkarta, Inc.



EN
04/11/2021

Underlying

NKTXNkarta

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nkarta

 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Third Quarter 2025 Financial Results and Corporate High...

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights  Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamideEnrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to guide dose escalation Initial data for NKX019 in multiple autoimmune indications expected to be presented at a medical conf...

November 10, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in November Investor Conferences

Nkarta to Participate in November Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen’s Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s web...

October 30, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Announces Poster Presentation at Upcoming American College of R...

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting. Nkarta will present clinical data showing that the company’s investigational therapy, NKX019, achieved robust pathogenic B-...

October 22, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta to Participate in a September Investor Conference

Nkarta to Participate in a September Investor Conference SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 9, 20258:30 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, , and a replay will be archived on the website for approximately 90 ...

September 2, 2025 1 EN
 PRESS RELEASE
Free
NKTX NKARTA

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Hig...

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter and year ended June 30, 2025. “We rema...

August 12, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch